In a report released yesterday, James Orsborne from Stifel Nicolaus maintained a Buy rating on Open Orphan Plc (HVO – Research Report), with a price target of p30.00.
James Orsborne has given his Buy rating due to a combination of factors that highlight the potential for growth and value in Open Orphan Plc. The company’s strategic acquisitions, particularly of CRS and Cryostore, have diversified its business model, setting a solid foundation for achieving its ambitious revenue target of £100 million by 2028. This diversification reduces dependency on larger contracts and enhances its ability to capture more of the value chain in the CRO market.
Moreover, the company’s core HCT business is showing promising signs, with significant revenue coverage for 2025 and a strong pipeline of opportunities. The recent ILiAD Biotechnologies contract, potentially the largest to date, underscores hVIVO’s leading position in the HCT space and could set a precedent for future Phase III trials. Despite a challenging funding environment, the current share price is seen as an attractive entry point, with the potential for top-line growth and margin expansion driving earnings growth from 2026 onwards.
According to TipRanks, Orsborne is ranked #9047 out of 9390 analysts.